Literature DB >> 8285613

Activities of antimicrobial agents against clinical isolates of Mycobacterium haemophilum.

E M Bernard1, F F Edwards, T E Kiehn, S T Brown, D Armstrong.   

Abstract

Mycobacterium haemophilum, first described in 1978, can cause severe infections of skin, respiratory tract, bone, and other organs of immunocompromised patients. There is no standardized antimicrobial susceptibility test, and for the 27 reported cases, a variety of test methods have been used. This paper reports the in vitro test results for 17 isolates of M. haemophilum recovered from 12 patients in the New York City area. MICs of 16 antimicrobial agents were determined in microtiter trays containing Middlebrook 7H9 broth plus 60 microM hemin, inoculated with 10(6) CFU of the organism per ml and incubated at 30 degrees C for 10 days. Ethambutol, ethionamide, tetracycline, cefoxitin, and trimethoprim-sulfamethoxazole were inactive against initial isolates from the 12 patients. Isoniazid was weakly active with a MIC for 50% of strains tested (MIC50) of 8 micrograms/ml and a MIC90 of > 32 micrograms/ml. Three quinolones, ciprofloxacin, ofloxacin, and sparfloxacin, were moderately active with MIC50s of 2 to 4 micrograms/ml and MIC90s of 4 to 8 micrograms/ml. Amikacin and clofazamine were active with MIC90s of 4 and 2 micrograms/ml, respectively. Clarithromycin was the most active macrolide with a MIC90 of < or = 0.25 microgram/ml. The MIC90 of azithromycin was 8 micrograms/ml, and the MIC90 of erythromycin was 4 micrograms/ml. The rifamycins were active with a MIC90 of 1 microgram/ml for rifampin and one of < or = 0.03 micrograms/ml for rifabutin. For a second isolate from the skin of one patient and a isolate from an autopsy culture of the spleen of a second patient, MICs of rifampin and rifabutin were > 16 microgram/ml, whereas initial isolates were inactivated by low concentrations of the rifamycins. Both patients had been treated for several months with several antimicrobial agents, including a rifamycin.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8285613      PMCID: PMC192386          DOI: 10.1128/AAC.37.11.2323

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  21 in total

1.  The antagonism of the tuberculostatic action of isoniazid by Hemin.

Authors:  M W FISHER
Journal:  Am Rev Tuberc       Date:  1954-03

2.  Unusual mycobacteria in 5 cases of opportunistic infections.

Authors:  A Mezo; F Jennis; S W McCarthy; D J Dawson
Journal:  Pathology       Date:  1979-07       Impact factor: 5.306

3.  The skin and immunosuppression.

Authors:  B K Walder; D Jeremy; J A Charlesworth; G J Macdonald; B A Pussell; M R Robertson
Journal:  Australas J Dermatol       Date:  1976-12       Impact factor: 2.875

4.  Skin lesions caused by Mycobacterium haemophilum.

Authors:  B R Davis; J Brumbach; W J Sanders; E Wolinsky
Journal:  Ann Intern Med       Date:  1982-11       Impact factor: 25.391

5.  Infection by Mycobacterium haemophilum, a metabolically fastidious acid-fast bacillus.

Authors:  M T Moulsdale; J M Harper; G N Thatcher; B L Dunn
Journal:  Tubercle       Date:  1983-03

6.  Mycobacteria with a growth requirement for ferric ammonium citrate, identified as Mycobacterium haemophilum.

Authors:  D J Dawson; F Jennis
Journal:  J Clin Microbiol       Date:  1980-02       Impact factor: 5.948

7.  Varied presentations and responses to treatment of infections caused by Mycobacterium haemophilum in patients with AIDS.

Authors:  L L Dever; J W Martin; B Seaworth; J H Jorgensen
Journal:  Clin Infect Dis       Date:  1992-06       Impact factor: 9.079

8.  Osteomyelitis caused by Mycobacterium haemophilum: successful therapy in two patients with AIDS.

Authors:  R L Yarrish; W Shay; V J LaBombardi; M Meyerson; D K Miller; D Larone
Journal:  AIDS       Date:  1992-06       Impact factor: 4.177

9.  New characteristics of Mycobacterium haemophilum.

Authors:  C G Ryan; B W Dwyer
Journal:  J Clin Microbiol       Date:  1983-10       Impact factor: 5.948

10.  Mycobacterium haemophilum causing lymphadenitis in an otherwise healthy child.

Authors:  D J Dawson; Z M Blacklock; D W Kane
Journal:  Med J Aust       Date:  1981-09-19       Impact factor: 7.738

View more
  13 in total

1.  Differential Sensitivity of Mycobacteria to Isoniazid Is Related to Differences in KatG-Mediated Enzymatic Activation of the Drug.

Authors:  Tali H Reingewertz; Tom Meyer; Fiona McIntosh; Jaryd Sullivan; Michal Meir; Yung-Fu Chang; Marcel A Behr; Daniel Barkan
Journal:  Antimicrob Agents Chemother       Date:  2020-01-27       Impact factor: 5.191

Review 2.  Epidemiology of infection by nontuberculous mycobacteria.

Authors:  J O Falkinham
Journal:  Clin Microbiol Rev       Date:  1996-04       Impact factor: 26.132

3.  The Brief Case: Disseminated Mycobacterium haemophilum Infection in a Kidney Transplant Recipient.

Authors:  Samantha E Jacobs; Elaine Zhong; Choli Hartono; Michael J Satlin; Cynthia M Magro; Stephen G Jenkins; Lars F Westblade
Journal:  J Clin Microbiol       Date:  2017-12-26       Impact factor: 5.948

Review 4.  Mycobacterium haemophilum: microbiology and expanding clinical and geographic spectra of disease in humans.

Authors:  M A Saubolle; T E Kiehn; M H White; M F Rudinsky; D Armstrong
Journal:  Clin Microbiol Rev       Date:  1996-10       Impact factor: 26.132

5.  Lesser known mycobacteria.

Authors:  B Watt
Journal:  J Clin Pathol       Date:  1995-08       Impact factor: 3.411

Review 6.  Clinical manifestations, diagnosis, and treatment of Mycobacterium haemophilum infections.

Authors:  Jerome A Lindeboom; Lesla E S Bruijnesteijn van Coppenraet; Dick van Soolingen; Jan M Prins; Eduard J Kuijper
Journal:  Clin Microbiol Rev       Date:  2011-10       Impact factor: 26.132

Review 7.  Mycobacterium haemophilum: an emerging pathogen.

Authors:  T E Kiehn; M White
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1994-11       Impact factor: 3.267

8.  Case of pyomyositis due to Mycobacterium haemophilum in a renal transplant recipient.

Authors:  Eun-Young Jang; Sang-Oh Lee; Seong-Ho Choi; Heungsup Sung; Mi-Na Kim; Bum-Joon Kim; Sang-Ho Choi; Yang Soo Kim; Jun Hee Woo
Journal:  J Clin Microbiol       Date:  2007-09-26       Impact factor: 5.948

9.  Restriction fragment length polymorphism analysis of clinical isolates of Mycobacterium haemophilum.

Authors:  K Kikuchi; E M Bernard; T E Kiehn; D Armstrong; L W Riley
Journal:  J Clin Microbiol       Date:  1994-07       Impact factor: 5.948

10.  Intracellular growth and cytotoxicity of Mycobacterium haemophilum in a human epithelial cell line (Hec-1-B).

Authors:  L J Fischer; F D Quinn; E H White; C H King
Journal:  Infect Immun       Date:  1996-01       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.